论文部分内容阅读
目的评价头孢哌酮/舒巴坦、氨曲南和头孢他啶治疗肿瘤患者下呼吸道感染的所产生的经济效果。方法选择我院恶性肿瘤伴下呼吸道感染患者120例,随机分为头孢哌酮/舒巴坦组(n=4)、氨曲南组(n=4)共3组,运用药物经济学方法进行成本-效果分析。结果3种方案的成本-效果比(C/E)分别为54.75元、60.73元、55.43元,总有效率分别为85.00%、90.00%、82.50%。结论头孢哌酮/舒巴坦组治疗效果最佳。
Objective To evaluate the economic effects of cefoperazone / sulbactam, aztreonam and ceftazidime in the treatment of lower respiratory tract infections in cancer patients. Methods A total of 120 patients with malignant neoplasm with lower respiratory tract infection in our hospital were randomly divided into three groups: cefoperazone / sulbactam (n = 4) and aztreonam (n = 4) Cost-effectiveness analysis. Results The cost-effectiveness ratio (C / E) of the three schemes were 54.75 yuan, 60.73 yuan and 55.43 yuan, respectively. The total effective rates were 85.00%, 90.00% and 82.50% respectively. Conclusion Cefoperazone / sulbactam treatment is the best.